Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by Defense World Staff on May 23rd, 2023

Repligen Co. (NASDAQ:RGEN – Get Rating) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $208.56.

A number of research firms recently weighed in on RGEN. TheStreet lowered shares of Repligen from a “b-” rating to a “c+” rating in a report on Monday, May 8th. Royal Bank of Canada lowered their price target on shares of Repligen from $170.00 to $157.00 in a report on Wednesday, May 3rd. StockNews.com began coverage on shares of Repligen in a report on Thursday, May 18th. They set a “sell” rating for the company. Benchmark lowered their price target on shares of Repligen from $230.00 to $210.00 in a report on Wednesday, May 3rd. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Repligen from $180.00 to $165.00 in a report on Wednesday, May 3rd.

Repligen Stock Up 4.7 %

Repligen stock opened at $166.74 on Tuesday. Repligen has a 52-week low of $137.65 and a 52-week high of $262.26. The firm has a fifty day moving average of $163.34 and a 200-day moving average of $173.07. The firm has a market capitalization of $9.28 billion, a P/E ratio of 56.52, a PEG ratio of 2.81 and a beta of 1.08.

Repligen (NASDAQ:RGEN – Get Rating) last released its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.05. The company had revenue of $182.70 million during the quarter, compared to analyst estimates of $181.43 million. Repligen had a net margin of 21.58% and a return on equity of 9.14%. The business’s quarterly revenue was down 11.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.92 earnings per share. On average, research analysts expect that Repligen will post 2.37 EPS for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus purchased 500 shares of Repligen stock in a transaction dated Monday, May 8th. The shares were bought at an average cost of $156.18 per share, for a total transaction of $78,090.00. Following the transaction, the director now owns 1,611 shares in the company, valued at approximately $251,605.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Signaturefd LLC lifted its position in shares of Repligen by 13.8% in the 3rd quarter. Signaturefd LLC now owns 469 shares of the biotechnology company’s stock worth $88,000 after buying an additional 57 shares during the last quarter. IFP Advisors Inc lifted its position in Repligen by 34.3% in the 3rd quarter. IFP Advisors Inc now owns 227 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 58 shares during the last quarter. State of Alaska Department of Revenue lifted its position in Repligen by 0.9% in the 4th quarter. State of Alaska Department of Revenue now owns 7,226 shares of the biotechnology company’s stock valued at $1,223,000 after purchasing an additional 65 shares during the last quarter. Arizona State Retirement System lifted its position in Repligen by 0.5% in the 3rd quarter. Arizona State Retirement System now owns 14,311 shares of the biotechnology company’s stock valued at $2,678,000 after purchasing an additional 67 shares during the last quarter. Finally, Lmcg Investments LLC lifted its position in Repligen by 2.4% in the 1st quarter. Lmcg Investments LLC now owns 2,901 shares of the biotechnology company’s stock valued at $488,000 after purchasing an additional 67 shares during the last quarter. 91.00% of the stock is currently owned by institutional investors.

About Repligen

(Get Rating)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.